MedTrace Logo

TRimetazidine for acUte on Chronic Liver Failure STudy

NCT03737448 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-03-04

No results posted yet for this study

Summary

The study will assess the pharmacokinetics (PK), tolerability, and safety of oral trimetazidine administered to subjects with AD (ACLF Grade 0) or with ACLF Grade 1 or 2.

Conditions

  • Acute-On-Chronic Liver Failure

Interventions

DRUG

Trimetazidine

Subjects with receive up to 60 mg daily

Sponsors & Collaborators

  • Martin Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Martin Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-28
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03737448 on ClinicalTrials.gov